Rasburicase Treatment in Chronic Gouty Arthritis
Efficacy and Safety of Rasburicase in the Treatment of Chronic Gouty Arthritis: A Multicenter Randomized Controlled Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Qianhua Li, M.D.&Ph.D
- Phone Number: 862081332572
- Email: liqianhua@mail.sysu.edu.cn
Study Locations
-
-
Guangdong
-
Foshan, Guangdong, China
- Not yet recruiting
- Shunde Hospital of Southern Medical University
-
Contact:
- Bin Yang, M.D.&Ph.D
- Phone Number: 2075722318000
-
Principal Investigator:
- Bin Liu, M.D.&Ph.D
-
Guangzhou, Guangdong, China, 510120
- Recruiting
- Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
-
Contact:
- Li Qianhua
- Phone Number: 862081332572
- Email: sumsliqianh@163.com
-
Guangzhou, Guangdong, China
- Not yet recruiting
- Panyu Central Hospital
-
Contact:
- Haijun Liu, M.D.&Ph.D
- Phone Number: 862034858888
- Email: kayjun0753@126.com
-
Principal Investigator:
- Haijun Liu, M.D.&Ph.D
-
Shanwei, Guangdong, China, 516600
- Not yet recruiting
- Shenshan Medical Center
-
Contact:
- Yingqian Mo, M.D.&Ph.D
- Phone Number: 866603863000
- Email: moyingq@mail.sysu.edu.cn
-
Principal Investigator:
- Yingqian Mo, M.D.&Ph.D
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Written informed consent must be obtained before any assessment is performed, able to understand and comply with the requirements of the study;
- Male and female patients 18 to 70 years of age;
- Fulfill the ACR/EULAR 2015 gout classification criteria;
- Tophi detected by physical examination;
- Serum urate>300μmol/L (5mg/dl) after one-month maximum dose of urate-lowering therapy (allopurinol 600mg/d or febuxostat 80mg/d in combination with benzbromarone 100mg/d) unless intolerable OR no reduction in size of tophi after serum urate<300μmol/L (5mg/dl) for six month;
Exclusion Criteria:
- Pregnant women, lactating women, and men or women who have recently prepared for pregnancy;
- Abnormal liver function with AST, ALT, and GGT >3 times ULN;
- Blood WBC<4.0×10^9/L, and/or hemoglobin <90g/L, and/or platelets;<100×10^9/L; or other hematologic disorders;
- eGFR<15 ml/min;
- Receive following medications: azathioprine, mercaptopurine, cyclosporine, pyrazinamide, ethambutol and sulfamethoxazole
- Psychiatric disorders, history of alcoholism, drug or other substance abuse
- Immunodeficiency diseases, uncontrolled infection, etc;
- Sericosis, glucose-6-phosphate dehydrogenase activity deficiency
- Allergy to biological agents and chronic active urticaria.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: Group A
Rasburicase treatment at week 1, 4 and 8 with stable dose oral urate-lowering therapy for 24 weeks.
|
Rasburicase 1.5 mg/day for 3 consecutive days at scheduled times.
|
|
Other: Group B
Rasburicase treatment at week 12, 16 and 20 with stable dose oral urate-lowering therapy for 24 weeks.
|
Rasburicase 1.5 mg/day for 3 consecutive days at scheduled times.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Monosodium urate crystal volume change evaluated by dual energy CT
Time Frame: Baseline to week 12 and week 12 to week 24
|
Dual energy CT at baseline, week 12 and week 24
|
Baseline to week 12 and week 12 to week 24
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Tophus volume change evaluated by physical examination
Time Frame: Baseline to week 12 and week 12 to week 24
|
Baseline to week 12 and week 12 to week 24
|
|
|
The percentage of patients who have at least one tophi disappeared
Time Frame: Baseline to week 12 and week 12 to week 24
|
Baseline to week 12 and week 12 to week 24
|
|
|
The percentage of patients who had achieved serum urate concentrations less than 300 μmol/L (5mg/dl) after 3 months of rasburicase treatment
Time Frame: Baseline to week 12 and week 12 to week 24
|
Baseline to week 12 and week 12 to week 24
|
|
|
Number of gout flare
Time Frame: Baseline to week 12 and week 12 to week 24
|
Baseline to week 12 and week 12 to week 24
|
|
|
Change of patient global assessment
Time Frame: Baseline to week 12 and week 12 to week 24
|
The patient global assessment is given as a single question, scored from 0-10, with higher numbers representing worse perceived disease activity or overall health.
|
Baseline to week 12 and week 12 to week 24
|
|
Change of physician global assessment
Time Frame: Baseline to week 12 and week 12 to week 24
|
The physician global assessment is given as a single question, scored from 0-10, with higher numbers representing worse perceived disease activity or overall health.
|
Baseline to week 12 and week 12 to week 24
|
|
Change of Visual Analog Scale (VAS) for Pain in gout flare
Time Frame: Baseline to week 12 and week 12 to week 24
|
Visual Analog for Pain consists of a horizontal line, usually 100mm in length.
The left end of the line signifies no pain while the right end signifies the worst possible pain.
|
Baseline to week 12 and week 12 to week 24
|
|
Change of global functional status
Time Frame: Baseline to week 12 and week 12 to week 24
|
The criteria are as follows: class I = able to perform usual activities of daily living (self-care, vocational, and avocational); class II = able to perform usual self-care and vocational activities, but limited in avocational activities; class III = able to perform usual self-care activities but limited in vocational and avocational activities; class IV = limited in ability to perform usual self-care, vocational, and avocational activities.
|
Baseline to week 12 and week 12 to week 24
|
|
Change of Short Form 12 health survey score
Time Frame: Baseline to week 12 and week 12 to week 24
|
Baseline to week 12 and week 12 to week 24
|
|
|
Change of Tophus Impact Questionnaire (TIQ)-20 score
Time Frame: Baseline to week 12 and week 12 to week 24
|
Baseline to week 12 and week 12 to week 24
|
|
|
Adverse event
Time Frame: Baseline to week 12 and week 12 to week 24
|
Baseline to week 12 and week 12 to week 24
|
|
|
Severe adverse event
Time Frame: Baseline to week 12 and week 12 to week 24
|
Baseline to week 12 and week 12 to week 24
|
|
|
Number of patients who have positive anti-rasburicase antibodies
Time Frame: Baseline to week 12 and week 12 to week 24
|
Baseline to week 12 and week 12 to week 24
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Qianhua Li, M.D.&Ph.D, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2021-KY-097-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.